Basilea Pharmaceutica Ltd (PK5)
FSX
69.70
-0.50 (-0.71%)
Closed
Oct 7, 2026
Day's Range
69.7069.70
52 wk Range
47.8073.40
Financial Statements - PK5 - Basilea Pharmaceutica Ltd
Revenue
232.38M▲ 11.4%
Net Income
40.24M▼ 48.1%Net Margin 17.3%
EBITDA
51.04M▼ 23.0%
Free Cash Flow
59.22M▼ 18.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Sales | 232.38M | 208.54M | 157.63M | 158.01M |
| Cost of Goods | 39.32M | 38.68M | 26.79M | 26.31M |
| Gross Profit | 193.05M | 169.86M | 130.84M | 131.70M |
 Operating Expense | - | - | - | - |
| Operating Income | 51.54M | 61.17M | 19.20M | 19.82M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 45.87M | 60.26M | 10.46M | 12.94M |
| Income Tax | 5.63M | -17.33M | 10K | -48.12K |
| Net Income | 40.24M | 77.59M | 10.45M | 12.99M |
| EPS Basic | - | 6.42 | 0.87 | 1.02 |
| EPS Diluted | - | 5.83 | 0.86 | 1.02 |
| Basic Shares Outstanding | - | 12.08M | 11.99M | 12.68M |
| Diluted Shares Outstanding | - | 12.08M | 11.99M | 12.68M |
| Ebit | 49.23M | 64.60M | 21.66M | 23.47M |
| Ebitda | 51.04M | 66.33M | 23.24M | 24.64M |
| Net Income Continuous Operations | 40.24M | 77.59M | 10.45M | 12.99M |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
